In a report published by the US Institute for Clinical and Economic Review (ICER), healthcare experts stated that the recently approved gene therapy for Leber’s… Read More »Review of price tag for Spark Therapeutics’ gene therapy treatment (Luxturna, $850,000 per patient) suggests a discount of up to 90% in certain cases.
Collaborative clinical research by clinicians based in Tel Aviv University, Israel, University of Buenos Aires, Argentina, the University of Leipzig, Germany and the University of… Read More »Biomarkers of metabolism, easily detectable with SD-OCT, indicate association with successful treatment of DME with DEX implant.
Researchers, led by investigators at the Schepens Eye Research Institute of Massachusetts Eye and Ear, and the Department of Ophthalmology, Harvard Medical School, Boston, have… Read More »CRISPR / Cas 9 gene editing technology shows promising anti-VEGF affects in lab models of angiogenesis.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 19th, 2018 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »January 19th, 2018: “EURETINA-Brief”© Issue No. 169
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has indicated a price tag of $850,000 per patient for its new gene therapy… Read More »Spark Therapeutics proposes price tag of $850,000 per patient for new gene therapy treatment
A clinical trial study, entitled “Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)”, has reported topline results… Read More »Phased I/II clinical trial results for treatment of wet AMD with topical small molecule inhibitor of integrin αvβ3
Researchers led by investigators at the Institute for Vascular Signaling, Goethe University, Frankfurt, Germany, have identified an enzyme, “soluble epoxide hydrolase” (sEH), to be involved… Read More »Inhibition of soluble epoxide hydrolase (sEH) may slow progression of diabetic retinopathy
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 3rd, 2018 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »January 3rd, 2018: “EURETINA-Brief”© Issue No. 168
GenSight Biologics (Euronext: SIGHT) have reported 30 months of follow-up data from a Phase I/II clinical trial with their treatment (GS010) in patients with Leber… Read More »French biopharmaceutical company, GenSight Biologics, reports long-term data for gene therapy treatment of LHON
Foundation Fighting Blindness USA (FFB), a US patient organisation advocating supports and research for individuals with retinal diseases, has openly criticized plans by the Trump… Read More »Patient organization fights to preserve pharmaceutical tax credits for development of orphan therapies in ophthalmology